Q32 Bio Inc.

QTTB

US7469641051

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 17/01/2026 am IST			5-day change	1st Jan Change
3.600 ^USD	0.00%		0.00%	+8.43%

20/12	Mark Iwicki Withdraws Resignation as Chair of the Board and Compensation Committee, as Well as a Member of the Audit Committee of Q32 Bio Inc., Effective December 17, 2025	CI
19/12	Q32 Bio Inc.(NasdaqCM:QTTB) dropped from NASDAQ Biotechnology Index	CI

Sector Update: Health Care Stocks Retreat Wednesday Afternoon

Published on 12/12/2024 at 12:20 am IST - Modified on 12/12/2024 at 01:43 am IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Q32 Bio Inc.

20/12	Mark Iwicki Withdraws Resignation as Chair of the Board and Compensation Committee, as Well as a Member of the Audit Committee of Q32 Bio Inc., Effective December 17, 2025	CI
19/12	Q32 Bio Inc.(NasdaqCM:QTTB) dropped from NASDAQ Biotechnology Index	CI
02/12	Top Midday Gainers	MT
01/12	Q32 Bio Inc. Sells Complement Inhibitor Adx-097	CI
01/12	Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal	MT
01/12	Akebia announces establishment of rare kidney disease pipeline	RE
01/12	Q32 Bio sells complement inhibitor Adx-097	RE
01/12	Top Premarket Gainers	MT
13/11	Q32 Bio Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
21/25/21	Q32 Bio Inc. Announces Completion of Enrollment in Part B of Signal-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata	CI
06/25/06	Q32 Bio Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
06/25/06	Q32 Bio reports second quarter 2025 financial results and provides corporate update	RE
11/25/11	Top Premarket Decliners	MT
10/25/10	Inventiva Names Jason Campagna Chief Medical Officer	MT
25/25/25	Q32 Bio Announces Executive Changes	CI
23/25/23	OXB US Inc completed the acquisition of remaining 10% of OXB US LLC from Q32 Bio Inc..	CI
23/25/23	Oxford Biomedica Takes Full Ownership of US Subsidiary	MT
08/25/08	Q32 Bio Reports First Quarter 2025 Financial Results And Provides Corporate Update	RE
08/25/08	Q32 Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
30/25/30	Q32 Bio Announces FDA Fast Track Designation Granted To Bempikibart (ADX-914) For The Treatment Of Alopecia Areata	RE
30/25/30	Q32 Bio Inc. Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata	CI
26/25/26	Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025	RE
26/25/26	Q32 Bio Inc Announces Resignation of Mark Iwicki from the Board of Directors	CI
16/25/16	Q32 Bio Doses First Patients In Both Part A Open-Label Extension And Part B Of Signal-Aa Phase 2A Trial	RE
16/25/16	Q32 Bio Inc. Doses First Patients in Both Part A Open-Label Extension and Part B of Signal-Aa Phase 2A Trial Evaluating Bempikibart in Alopecia Areata	CI

Q32 Bio Inc. is a clinical-stage biotechnology company. The Company is engaged in developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase II trials for the treatment of atopic dermatitis and alopecia areata. Its program for innate immunity, ADX-097, is based on a platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade. The Company has completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers.

Employees

Sector

Biotechnology & Medical Research

Calendar

17/03 - Q4 2025 Earnings Release (Projected)

More about the company